Overview

Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
The main objective of the study is to evaluate safety and tolerability of blinatumomab in adult Japanese participants with newly diagnosed B-ALL.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen
Treatments:
blinatumomab